Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budigalimab (ABBV-181) in HIV-1 infected adults
NCT04223804Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of budigalimab in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Study Drug-Related Adverse Events Grade 3 or Higher at 44 weeks, Number of Participants with Study Drug-Related Immune-Related Adverse Events at 44 weeks and 6 more. Started Jan 2020; status: completed.
02
Drugs
budigalimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04223804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223804.